Literature DB >> 20185425

A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.

C Tabata1, N Hirayama, R Tabata, A Yasumitsu, S Yamada, A Murakami, S Iida, K Tamura, K Fukuoka, K Kuribayashi, T Terada, T Nakano.   

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy; therefore, diagnosing MPM early is very important. We have previously reported that angiopoietin (Ang)-1 was correlated with bleomycin-induced pulmonary fibrosis. Here, we investigated the association of Ang-1 with the development of MPM cells, which originate from mesenchymal cells similar to lung fibroblasts, and demonstrated that Ang-1 stimulated the growth and migration of MPM cells in vitro. We also demonstrated that patients with MPM had significantly higher serum levels of Ang-1 in comparison to a population who had been exposed to asbestos but had not developed MPM. The patients with advanced-stage MPM showed higher levels of Ang-1 than the early-stage MPM patients and the Kaplan-Meier method revealed a significant correlation between serum Ang-1 levels and survival. We propose the possibility that Ang-1 plays an important role in MPM tumour growth and our data suggest that the serum concentration of Ang-1 could be useful as prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185425     DOI: 10.1183/09031936.00154009

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis.

Authors:  Hidenori Matsuzaki; Megumi Maeda; Suni Lee; Yasumitsu Nishimura; Naoko Kumagai-Takei; Hiroaki Hayashi; Shoko Yamamoto; Tamayo Hatayama; Yoko Kojima; Rika Tabata; Takumi Kishimoto; Junichi Hiratsuka; Takemi Otsuki
Journal:  J Biomed Biotechnol       Date:  2012-02-06

Review 2.  Asbestos induces reduction of tumor immunity.

Authors:  Naoko Kumagai-Takei; Megumi Maeda; Ying Chen; Hidenori Matsuzaki; Suni Lee; Yasumitsu Nishimura; Junichi Hiratsuka; Takemi Otsuki
Journal:  Clin Dev Immunol       Date:  2011-10-04

3.  Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells.

Authors:  Joman Javadi; Ghazal Heidari-Hamedani; Angelika Schmalzl; Tünde Szatmári; Muzaffer Metintas; Pontus Aspenström; Anders Hjerpe; Katalin Dobra
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

4.  CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Authors:  Vishwa Jeet Amatya; Yukio Takeshima; Keisuke Aoe; Nobukazu Fujimoto; Toshihiro Okamoto; Taketo Yamada; Takumi Kishimoto; Chikao Morimoto; Kouki Inai
Journal:  Oncol Rep       Date:  2012-10-31       Impact factor: 3.906

5.  Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

Authors:  Italia Grenga; Anna R Kwilas; Renee N Donahue; Benedetto Farsaci; James W Hodge
Journal:  J Immunother Cancer       Date:  2015-11-17       Impact factor: 13.751

6.  Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

Authors:  Sophia Magkouta; Apostolos Pappas; Ioannis S Pateras; Androniki Kollintza; Charalampos Moschos; Maria-Eleni Vazakidou; Vasiliki Karavana; Vassilis G Gorgoulis; Ioannis Kalomenidis
Journal:  Oncotarget       Date:  2018-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.